From the FDA Drug Label
The recommended dosage is 175 mcg YUPELRI (one 175 mcg unit‑dose vial) administered by oral inhalation once daily by nebulizer using a mouthpiece YUPELRI should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor The safety and efficacy of YUPELRI have been established in clinical trials when administered using the PARI LC® Sprint nebulizer with a mouthpiece and the PARI Trek® S compressor
The recommended use and dosage of Yupelri (revefenacin) via a nebulizer for chronic obstructive pulmonary disease (COPD) is 175 mcg once daily by oral inhalation using a standard jet nebulizer with a mouthpiece connected to an air compressor, such as the PARI LC® Sprint nebulizer with a mouthpiece and the PARI Trek® S compressor 1.
- Key points:
- Dosage: 175 mcg once daily
- Administration: Oral inhalation via a standard jet nebulizer with a mouthpiece connected to an air compressor
- Nebulizer compatibility: Established with PARI LC® Sprint nebulizer and PARI Trek® S compressor 1
From the Research
Yupelri (revefenacin) is recommended as a once-daily maintenance treatment for COPD at a dosage of 175 mcg (3 mL of the solution) administered via a standard jet nebulizer connected to an air compressor. The medication should be taken once every 24 hours, with each treatment session typically lasting 8-10 minutes. Patients should use only the Yupelri solution provided in the vial without mixing it with other medications in the nebulizer. The drug works as a long-acting muscarinic antagonist (LAMA) that helps relax the muscles around the airways, making breathing easier for those with COPD. It's essential to use Yupelri regularly as prescribed, even when symptoms improve, as it's a maintenance medication rather than a rescue inhaler for sudden breathing problems. Patients should continue their other COPD medications unless directed otherwise by their healthcare provider. Common side effects may include cough, headache, and back pain. If a dose is missed, patients should take it as soon as possible but should not double the dose to make up for a missed one. According to the most recent study 2, revefenacin at the approved dose is generally well-tolerated and safe with minimal adverse events, which supports its use as a once-daily nebulized LAMA for the treatment of moderate to severe stable COPD.
Some key points to consider when using Yupelri (revefenacin) include:
- The medication should be administered via a standard jet nebulizer connected to an air compressor, as specified in the study 3.
- The recommended dosage is 175 mcg (3 mL of the solution) once daily, as indicated in the study 4.
- Patients should not mix the Yupelri solution with other medications in the nebulizer, as stated in the study 5.
- Common side effects may include cough, headache, and back pain, as reported in the study 2.
- If a dose is missed, patients should take it as soon as possible but should not double the dose to make up for a missed one, as recommended in the study 6.
Overall, Yupelri (revefenacin) is a safe and effective treatment option for patients with COPD, and its use as a once-daily nebulized LAMA can help improve lung function and reduce symptoms.